Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biospecifics Tech Cp (BSTC)

Biospecifics Tech Cp (BSTC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 477,574
  • Shares Outstanding, K 7,339
  • Annual Sales, $ 32,960 K
  • Annual Income, $ 20,050 K
  • 60-Month Beta 1.25
  • Price/Sales 13.18
  • Price/Cash Flow 21.23
  • Price/Book 4.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.94
  • Number of Estimates 1
  • High Estimate 0.94
  • Low Estimate 0.94
  • Prior Year 0.84
  • Growth Rate Est. (year over year) +11.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.30 +17.67%
on 01/27/20
65.87 -1.21%
on 02/14/20
+9.47 (+17.03%)
since 01/14/20
3-Month
51.89 +25.40%
on 01/08/20
65.87 -1.21%
on 02/14/20
+12.10 (+22.84%)
since 11/14/19
52-Week
45.81 +42.04%
on 10/24/19
73.31 -11.24%
on 02/19/19
-2.91 (-4.28%)
since 02/14/19

Most Recent Stories

More News
When Does Market Timing Actually Work? - February 05, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

CMD : 67.59 (+2.88%)
TRXC : 1.25 (+0.81%)
CSBR : 7.24 (-0.96%)
BSTC : 65.07 (-0.78%)
RDNT : 22.87 (+0.75%)
How to Time the Markets Like an Investing Pro - January 17, 2020

In the long-run, does consistent market timing really matter to be a successful investor?

TRXC : 1.25 (+0.81%)
CMD : 67.59 (+2.88%)
CSBR : 7.24 (-0.96%)
BSTC : 65.07 (-0.78%)
RDNT : 22.87 (+0.75%)
The Market Timing Secrets No One Talks About - December 24, 2019

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

CMD : 67.59 (+2.88%)
TRXC : 1.25 (+0.81%)
CSBR : 7.24 (-0.96%)
BSTC : 65.07 (-0.78%)
RDNT : 22.87 (+0.75%)
19.1% Return Seen to Date on SmarTrend Biospecifics Tec Call (BSTC)

SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on November 5th, 2019 at $50.10. In approximately 1 month, Biospecifics Tec has returned 19.09% as of today's recent price of $59.66....

BSTC : 65.07 (-0.78%)
Simple Market Timing Strategies That Work - December 04, 2019

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

RDNT : 22.87 (+0.75%)
TRXC : 1.25 (+0.81%)
CMD : 67.59 (+2.88%)
BSTC : 65.07 (-0.78%)
CSBR : 7.24 (-0.96%)
The Truth About Market Timing - November 14, 2019

In the long-run, does consistent market timing really matter to be a successful investor?

CMD : 67.59 (+2.88%)
TRXC : 1.25 (+0.81%)
BSTC : 65.07 (-0.78%)
CSBR : 7.24 (-0.96%)
RDNT : 22.87 (+0.75%)
BioSpecifics Technologies (BSTC) Q3 Earnings and Revenues Beat Estimates

BioSpecifics (BSTC) delivered earnings and revenue surprises of 13.33% and 6.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BSTC : 65.07 (-0.78%)
BioSpecifics Reports Third Quarter 2019 Financial and Operating Results

BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed...

BSTC : 65.07 (-0.78%)
BioSpecifics Technologies (BSTC) to Report Q3 Results: Wall Street Expects Earnings Growth

BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BSTC : 65.07 (-0.78%)
The Truth About Market Timing - October 24, 2019

In the long-run, does consistent market timing really matter to be a successful investor?

TRXC : 1.25 (+0.81%)
CMD : 67.59 (+2.88%)
CSBR : 7.24 (-0.96%)
BSTC : 65.07 (-0.78%)
RDNT : 22.87 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade BSTC with:

Business Summary

BIOSPECIFICS TECHNOLOGIES is engaged in the business of producing and licensing, for sale by other, a U.S. Food and Drug Administration (``FDA``) approved enzyme derived from collagenase, named Collagenase ABC, and researching, developing and clinically testing additional products derived therefrom for...

See More

Key Turning Points

2nd Resistance Point 66.55
1st Resistance Point 65.81
Last Price 65.07
1st Support Level 64.39
2nd Support Level 63.71

See More

52-Week High 73.31
Last Price 65.07
Fibonacci 61.8% 62.80
Fibonacci 50% 59.56
Fibonacci 38.2% 56.31
52-Week Low 45.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar